Svar Life Science at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Svar Life Science brings 2 presentations to ESGCT 2026 in Hamburg. Its contribution is assays that read out how a gene therapy behaves in human biology. Work includes profiling complement activation triggered by AAV and a dual-reporter potency assay built to reflect the mechanism, applied to retinal gene therapy.

OrganizationESGCT 2026 Attendance
Svar Life Science
Malmö, Sweden
svarlifescience.com
Tools & reagents
Makes complement and cell-based reporter assays and offers testing services, including AAV immunogenicity assays for antibodies and complement activation.
Poster
Wed Oct 28
1:30pm–3:30pm
A novel tool for complement activation profiling in AAV gene therapy
Immune responses to GT
Poster
Thu Oct 29
2:00pm–4:00pm
A dual-reporter platform for mechanism-reflective AAV potency assays: Application to retinal gene therapy
Other
Manufacturing, CMC and accessVectors and delivery (AAV, lentiviral, LNP)

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Svar Life Science

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction